GHK-Cu

GHK-Cu is a short, naturally occurring repair signal: three amino acids (glycyl-L-histidyl-L-lysine) holding a single copper ion ¹¹. The body releases it when connective tissue, the scaffold between cells called the extracellular matrix, is remodeled, and it instructs nearby cells to rebuild rather than break down tissue ¹⁰. Because copper is essential to the complex, an intact GHK-Cu solution has a pale blue color.

It was discovered in 1973 as a factor in human albumin that restored protein synthesis in aged liver tissue, and its structure in solution was solved in 1982 ⁹. In 1988, researchers showed it tells skin-building cells (fibroblasts) to make collagen, the main structural protein of skin, at very low concentrations ¹⁰.

Plasma levels of GHK average about 200 ng/mL in young adults and fall to around 80 ng/mL by age 60, a decline proposed as one reason tissues repair more slowly with age ⁸. That is the logic behind studying it as a replacement for a dwindling signal.

Today GHK-Cu is studied in three broad directions. Skin aging and wound healing have the most human evidence, including two small randomized trials in aesthetics and a meta-analysis of 22 studies ². Animal work covers inflammatory, antioxidant, and scarring conditions of the lung, gut, and muscle ¹⁵. And in brain-aging models, intranasal doses improved cognition in aged mice ¹⁶. A phase 2 trial for acute wounds is still recruiting with no efficacy results ¹.

GHK-Cu is a matrikine: a signaling fragment produced when the body's connective tissue is broken down and remodeled. The GHK sequence appears inside a chain of type I collagen, so the repair signal is released right at wound sites ¹⁰. In solution it holds one copper ion, which gives the intact complex its pale blue color ¹¹.

The central switch: SIRT1

The best-defined direct target is sirtuin-1 (SIRT1), an enzyme that removes acetyl tags from other proteins to change their activity ¹⁸. GHK-Cu binds and activates SIRT1, and that activation coordinates a repair program ¹⁵:

• Muscle: SIRT1 deacetylates FoxO3a and suppresses the protein break-down machinery (MuRF1, atrogin-1) ¹⁸.
• Antioxidant defense: Deacetylation of Nrf2, a master switch for antioxidant genes, turns on protective enzymes ¹⁸.
• Mitochondria: PGC-1a activation supports mitochondrial function ¹⁸.
• Gut and airway lining: SIRT1 reduces STAT3 phosphorylation to restore the tight-junction proteins (ZO-1, occludin) that seal the barrier between cells, and suppresses TGF-beta1/Smad signaling that drives scarring (fibrosis) ¹⁵.

In parallel, GHK-Cu dampens the inflammatory switches NF-kB p65 and p38 MAPK, lowering TNF-alpha and IL-6, and downregulates JAK1 signaling ¹³. This axis is conserved across species: in the worm C. elegans, the benefits require DAF-16 (the worm's FOXO protein) and SKN-1 (its Nrf2 equivalent), with more antioxidant enzymes and healthier mitochondria as a result ¹⁴.

A broad gene-expression shift

Rather than acting through a single receptor, GHK-Cu behaves like a broad coordinator. Gene-profiling studies found it changes expression of about 31% of human genes by 50% or more, with DNA-repair genes strongly biased upward and cancer-related sets shifted toward programmed cell death and growth control ³³.

Supporting actions

• Buffered copper delivery. GHK holds copper so cells can use it for copper-dependent enzymes like superoxide dismutase (an antioxidant) and lysyl oxidase (needed to cross-link collagen) while protecting against free-copper toxicity. In zebrafish, GHK rescued larvae from copper-induced heart toxicity ³⁴.
• New vessel growth (angiogenesis). It upregulates VEGF and FGF-2 and increased endothelial cell proliferation by about 33% in vitro ²⁵.
• Matrix rebuilding. It stimulates collagen types I, IV, and VII, elastin, and glycosaminoglycans, and rebalances the enzymes that break down matrix (MMPs) against their inhibitors (TIMPs) ². A liposomal formulation inhibited the matrix-degrading enzyme elastase by about 49% in vitro ²⁷.
• Direct antioxidant activity. It lowers reactive oxygen species and nitric oxide while raising superoxide dismutase and glutathione, partly through Nrf2 ²².

No formal human pharmacokinetic data exist, and effects are transient: in a rat knee study, benefits present at 6 weeks were gone by 12 weeks after dosing stopped ²⁴.

Skin aging and wrinkles (human trials). A meta-analysis of 22 studies (1,124 participants) reported large effect sizes for tissue regeneration, reduced inflammation, and regenerative gene expression ³. The aesthetics literature contains two small randomized trials showing reduced wrinkle volume and depth versus control and improved patient satisfaction after laser resurfacing ². A combined ferment-extract plus GHK-Cu cream also reduced wrinkles and improved skin barrier in a clinical study ²⁶. One counterpoint exists: a 13-participant post-laser split-face trial found no objective benefit ¹.

Wound healing. Strong in animals, limited in humans. Liposomal GHK-Cu closed scald wounds in mice by day 14 ²⁵. A phase 2 acute-wound trial is recruiting but has no results yet ¹. Reviews treat the short-term safety record as favorable ⁴.

Hair growth. An 18-participant split-face eyebrow study reported positive cosmetic hair outcomes, though the copper form was not defined ¹.

Lung, gut, and muscle (animal studies). Intraperitoneal doses attenuated cigarette-smoke emphysema ²⁰, bleomycin lung fibrosis ²¹, LPS acute lung injury ²², asthma airway remodeling ¹⁹, and silicosis ²³. In a colitis model, GHK-Cu improved the disease through SIRT1 and restoration of tight junctions ¹⁵. In smoking-exposed mice, 0.2-2 mg/kg rescued muscle dysfunction through SIRT1, and COPD patients had lower plasma GHK than healthy controls ¹⁸.

Brain aging (animal studies). Intranasal GHK improved cognition in aged mice ¹⁷ and reduced amyloid plaques and MCP-1 inflammation in an Alzheimer's model ¹⁶. Route matters: intranasal delivery gave sustained benefit while intraperitoneal was transient, with divergent gene programs in the hippocampus ¹².

Musculoskeletal (animal studies). Weekly intra-articular doses transiently improved rat ACL graft stiffness and laxity at 6 weeks; the benefit was lost by 12 weeks ²⁴. No human musculoskeletal data exist ⁵.

Lifespan (invertebrate). In C. elegans, GHK-Cu extended lifespan through the DAF-16/SKN-1 pathways and mitochondrial fusion ¹⁴.

The pattern is consistent: broad preclinical convergence on repair mechanisms, but human data remain thin and mostly cosmetic ¹.

Human evidence exists only for topical cosmetic use ². Beyond that, the protocol patterns below come from community practice or animal studies.

• Topical (human data). Community protocols use 1-3% w/v GHK-Cu creams or serums once or twice daily over 8-12 weeks (community protocol), while clinical wrinkle studies report reduced wrinkle volume and depth versus control ². A ferment extract plus GHK-Cu cream reduced wrinkles and improved barrier function in a clinical study ²⁶. Because the peptide is hydrophilic and crosses the skin's outer barrier poorly, delivery engineering matters: liposomal encapsulation and microneedling both improve uptake ⁶, and a 1:9 blend with low-molecular-weight hyaluronic acid increased collagen IV production 25-fold in vitro ²⁸.
• Subcutaneous (community protocol). No human trial has evaluated injected GHK-Cu, and no validated weight-based dosing exists ⁵. Community protocols typically use 1-2 mg once daily in 4-8 week courses, sometimes split as 5 days on and 2 days off, followed by an off period. Mesotherapy sessions use 1-5 mg. The timeline above details a representative cycle.
• Intranasal (animal). Cognitive studies in mice dose 15 mg/kg daily or three times weekly for 2-3 months ¹⁶.
• Intraperitoneal (animal). Lung and muscle studies use 0.2-20 mg/kg/day, often on alternate days ¹⁸.
• Intra-articular (animal). A rat ACL study injected 0.3 or 3 mg/mL weekly for four weeks ²⁴.

A conversion note: scaling the mouse muscle range by body surface area (dividing by 12.3) yields a human-equivalent estimate near 0.016-0.16 mg/kg. At 70 kg that is 1.2-11.4 mg/day, an envelope that contains the community 1-2 mg/day range, but this is extrapolation rather than validated dosing.

Comparisons across products are further complicated because formulations rarely report how much of the peptide is actually bound to copper, a variable that can change both activity and safety ¹.

GHK-Cu is supplied as a dry (lyophilized) powder that is reconstituted before research use. The standard diluent in community protocols is bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative; saline and phosphate-buffered saline also appear as injection vehicles in published animal studies.

Handling matters because the peptide is oxidation-sensitive, and the copper can dissociate from the complex, which inactivates it ¹. Practitioner guidance is to add diluent slowly down the vial wall and swirl gently rather than shake. The intact copper complex gives the solution a pale blue color, so loss of that color is a sign the copper has dissociated.

For storage, the lyophilized powder keeps long term at -20°C, or refrigerated at 2-8°C for shorter periods if kept dry and protected from light. Reconstituted solution belongs in the refrigerator at 2-8°C, protected from light, and should not be repeatedly frozen and thawed. Community protocols discard reconstituted vials after about 30 days, sooner with sterile water alone, and discard immediately on clouding, precipitation, or color change.

For injectable use, community protocols emphasize aseptic technique: a fresh sterile syringe and single-use needle for every injection, a wiped vial stopper and injection site, skin dried after the alcohol swab, and a 0.22 um sterile syringe filter between vial and syringe when the protocol calls for filtered preparation (community protocol). Vials are single-user, syringes and needles are never shared, and signs of injection-site infection, or a reaction that does not settle, end the course.

The calculator below converts a target dose into a draw volume for the vial and diluent you select.

No dedicated human drug-interaction studies exist for GHK-Cu, so most of what follows is inferred from mechanism and limited dermatologic observations.

• Copper chelators (EDTA, penicillamine, trientine). Chelators pull copper off the peptide, and EDTA has been shown to reverse GHK-Cu complexation. Because activity depends on the intact copper complex, this would functionally inactivate it ¹.
• Anti-VEGF agents. GHK-Cu promotes new vessel growth via VEGF and FGF-2 ²⁵, so it could theoretically oppose anti-angiogenic drugs. Relevant only to systemic use, and untested.
• SIRT1 modulators. Since GHK-Cu activates SIRT1 ¹⁸, SIRT1-activating compounds might add to its effects while SIRT1 inhibitors might blunt them. Untested.
• Vitamin C. Historical animal work combined copper peptides with ascorbate, but high-dose vitamin C can reduce Cu(II) to Cu(I), creating a theoretical pro-oxidant cycle. Moderate oral intakes appear unproblematic.
• Hyaluronic acid. A positive interaction: at a 1:9 ratio with low-molecular-weight HA, GHK-Cu boosted collagen IV production 25.4-fold in vitro ²⁸.
• Copper supplements. Free copper excess drives oxidative stress and gut-barrier disruption ³⁶; community guidance is to avoid stacking copper sources.
• Antibiotics. In pigs, inorganic dietary copper expanded antibiotic-resistance gene reservoirs in the gut, while the copper-peptide form was comparatively favorable ³⁶. Relevance to humans is unstudied.
• Chemotherapy. No clinical data exist. Because copper delivery modulates cancer-cell biology in vitro ³⁵, practitioner consensus is to avoid systemic GHK-Cu during active cancer treatment.
• Energy-based procedures. LED photoirradiation with copper peptide enhanced collagen synthesis in vitro ⁴⁸, but a post-laser human split-face trial was negative on objective endpoints ¹.

GHK-Cu does not appear to drive classic receptor desensitization, because it acts as a broad gene-expression regulator rather than a single-receptor agonist ¹. Cycling exists for other reasons:

• Effects fade after dosing stops. In rats, knee-ligament benefits present at 6 weeks were gone by 12 weeks after weekly injections ended ²⁴, supporting repeat courses rather than single treatments.
• Copper load. GHK binds copper at 1:1 stoichiometry ¹¹, so a 30-day course at 2 mg/day carries roughly 9-10 mg of elemental copper. Scheduled off periods cap cumulative copper exposure; the risky fraction is labile (unbound) copper, and that depends on formulation quality ¹.
• A narrow concentration window. In fibroblasts, collagen stimulation begins near 10^-12 M and peaks near 10^-9 M with no added benefit above that ¹⁰, so escalating the dose is not a substitute for cycling.
• Different programs, different durations. In aged mice, a 5-day intraperitoneal pulse activated repair-pathway genes while 8-week intranasal dosing altered mitochondrial and growth programs, with similar functional outcomes ¹².

Community schedules include subcutaneous courses of 30 days on and 30-45 days off, 4-6 week blocks with split weeks (5 days on, 2 off), topical use for 6-10 weeks with 2-4 week breaks, and mesotherapy sessions every 2-4 weeks for 4-6 sessions.

Signals that a course may have run its course: a plateau in skin or scar response, metallic taste, nausea, or fatigue, persistent injection-site irritation, or a completed course with no objective improvement, which mirrors the negative post-laser trial ¹. Plasma GHK declines by about 60% between ages 20 and 60 ⁸, so many protocols frame GHK-Cu as intermittent replacement rather than continuous therapy.

No published combination studies exist for any GHK-Cu stack, so the pairings below are inferred from mechanism and community practice.

• BPC-157. The most common community combination. Both are repair peptides with largely preclinical evidence and favorable short-term safety signals; BPC-157's strengths run toward gut and tendon repair, while GHK-Cu's are dermal matrix and antioxidant defense ⁴.
• TB-500 / TB-4. Orthopaedic reviews describe overlapping wound-healing and angiogenic mechanisms with no identified conflict.
• GH secretagogues (CJC-1295, ipamorelin, sermorelin). These act through the GH/IGF-1 axis, which does not share pathways with GHK-Cu, so theoretical conflict is low.
• Hyaluronic acid. The best-documented combination: at a 1:9 ratio with low-molecular-weight HA, GHK-Cu raised collagen IV expression 25.4-fold in fibroblasts and 2-fold in ex vivo skin ²⁸.
• Extracts and cosmetics. A Torilis japonica extract complexed with GHK-Cu suppressed Th2 cytokines and accelerated keratinocyte recovery in an atopic dermatitis model ⁴³, and a ferment extract plus GHK-Cu cream improved wrinkles and barrier function clinically ²⁶.
• Avoid stacking copper sources. Adding other copper peptides or copper supplements raises total copper load; in pigs, inorganic copper drove gut oxidative stress and antibiotic-resistance gene spread while the copper-peptide form did not ³⁶.

GHK-Cu is not FDA-approved as a drug for any indication ⁵. It is lawfully marketed as a cosmetic ingredient in anti-wrinkle, skin-care, and hair-care products, a channel where small copper peptides carry an excellent safety record ³⁵. Injected, intra-articular, and mesotherapy use sits outside any approved pathway and belongs to the unapproved direct-to-patient peptide market described in the sports-medicine literature ⁵.

The development pipeline is thin: a single phase 2 acute-wound trial (NCT07437586) is recruiting with no efficacy data, and registration alone is not evidence that a product works ¹. Two small randomized aesthetic trials exist, one showing wrinkle reduction and improved post-laser satisfaction, the other negative on objective endpoints ¹.

Internationally, no marketing authorization from the EMA, MHRA, PMDA, or TGA is documented in the reviewed literature, and the reviews found no country-specific bans ¹. In the EU cosmetic market, GHK-Cu is an established anti-aging ingredient in commercial products ³⁵.

For athletes: the WADA Prohibited List includes category S0 for substances without a government marketing authorization, but the reviewed literature does not establish whether GHK-Cu falls under S0, and it is not listed among peptide hormones. Competitive-eligibility implications remain unresolved ⁵.

GHK-Cu has roughly 50 years of cosmetic-use history with a favorable safety record ³⁵. Topical side effects are typically mild: transient redness, stinging, and tightness, worse on compromised or post-procedure skin. Systematic reviews of aesthetic studies report improved outcomes with no serious adverse events ², and a 2026 meta-analysis describes a favorable safety profile ³.

For injected use, the safety database is essentially absent: no human injection safety, pharmacokinetic, or dose-finding studies exist ⁵. Community reports describe injection-site tenderness, transient redness, itching, occasional bruising, and a self-limiting metallic taste, but these are anecdotal rather than trial data.

The central safety variable is copper. Each milligram of GHK-Cu carries about 0.16 mg of elemental copper at 1:1 binding ¹¹, and the toxicologically relevant fraction is unbound (labile) copper, which most commercial products do not report ¹. Rodent studies found no dose-limiting toxicity at intraperitoneal doses up to 20 mg/kg/day ²⁰, and in pigs, inorganic dietary copper drove gut oxidative stress and antibiotic-resistance gene spread while the copper-peptide form did not ³⁶.

Practitioner consensus contraindications include Wilson's disease and other copper-handling disorders, known hypersensitivity, active malignancy, and pregnancy or lactation. Caution applies in severe liver or kidney impairment, and concurrent copper sources should be tracked.

For injectable community protocols, practitioner consensus is to check copper, ceruloplasmin, zinc, and liver enzymes (ALT/AST) at baseline and every 8-12 weeks, stopping if copper or liver markers rise above reference or if persistent metallic taste, nausea, or unexplained fatigue appears. Topical use requires no laboratory monitoring.

Open questions remain: long-term human safety for any route, any injectable dose-response, drug interactions in general, and route-dependent biology, since intranasal and intraperitoneal GHK-Cu produced opposite hippocampal gene programs in mice ¹².